Regeneron drug tops rivals in some vision loss cases
February 18, 2015 at 17:00 PM EST
Regeneron Pharmaceuticals' top-selling eye drug, Eylea, bested Roche's Lucentis and Avastin in a U.S.-sponsored study in diabetes-related vision loss.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.